Clinical Trials Arena on MSN5d
Helicore doses first subject in Phase I trial of obesity treatmentUS-based biopharmaceutical company Helicore Biopharma has dosed the first subject in a randomised, first-in-human Phase I ...
These modules allow the ProteinReDiff framework to capture intricate protein–ligand interactions, improve the fidelity of ...
A novel protein cage system can control and visualize orientational changes in aromatic side chains upon ligand binding. By inducing coordinated molecular changes, this approach enables precise ...
Seth Wander, MD, PhD, discusses the significance of ESR1 mutations in patients with hormone receptor–positive, HER2-negative ...
Get Instant Summarized Text (Gist) A novel protein cage system enables control and visualization of aromatic side chain orientation changes upon ligand binding, enhancing fluorescence properties ...
News-Medical.Net on MSN15d
Novel cyclic peptide antagonist can be a promising therapeutic approach for MASHThe farnesoid X receptor (FXR) is a bile acid nuclear receptor that plays a crucial role in regulating bile acid and sterol metabolism.
Our methodologies include: Docking-Based Virtual Screens and Rescoring/Hit Analysis: Employing molecular docking simulations, we perform large-scale virtual screens to predict ligand binding poses and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback